NCT03420807 is a NA clinical trial of MHRC in Alzheimer Disease, sponsored by Optina Diagnostics Inc..

Who is sponsoring NCT03420807?

NCT03420807 is sponsored by Optina Diagnostics Inc..

What drugs are being tested in NCT03420807?

Interventions in NCT03420807: MHRC.

What condition does NCT03420807 study?

NCT03420807 studies Alzheimer Disease.

Is NCT03420807 still recruiting?

NCT03420807 is currently completed. Last updated 28 March 2023.

Last reviewed 2023-03-28 · How we verify

NCT03420807

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retinal Metabolic Imaging of Alzheimer Patient

Completed NA Last updated 28 March 2023

What this trial tests

NA trial testing MHRC in Alzheimer Disease in 49 participants. Completed in 12 March 2020.

Timeline

4 December 2017

Primary endpoint
12 March 2020

12 March 2020

Quick facts

Lead sponsor	Optina Diagnostics Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	49
Start date	4 December 2017
Primary completion	12 March 2020
Estimated completion	12 March 2020
Sites	1 location across Canada

Drugs / interventions tested

MHRC

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Optina Diagnostics Inc.

Who can join

Adults 50 to 90, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research project concerns the evaluation of the Metabolic Hyperspectral Retinal Camera (MHRC), a novel medical instrument from Optina Diagnostics, for the detection of beta-amyloid plaques, a hallmark of Alzheimer's disease (AD), in the retina. The experimental device, produces multiple images of the retina when subjected to light in very specific colors (90-100 specific colors typically) and may be used to identify specific biomarkers based on their unique spectral signature. The retina is an extension of the brain and is the only optically accessible nervous tissue. The MHRC could represent a simple and non-invasive tool to facilitate the diagnosis of AD.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ocular Manifestations of Alzheimer's and Other Neurodegenerative Diseases: The Prospect of the Eye as a Tool for the Early Diagnosis of Alzheimer's Disease.
Colligris P, Perez de Lara MJ, Colligris B, Pintor J. · · 2018 · cited 54× · PMID 30151279 · DOI 10.1155/2018/8538573
Retinal manifestations and their diagnostic significance in Alzheimer's disease.
Abhyankar SD, Little K, Stitt A, Bhatwadekar AD. · · 2025 · PMID 40799319 · DOI 10.1177/25424823251361937

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Optina Diagnostics Inc. trials

Trials by the same sponsor.

NCT06860568 — The GA in HSI Study · completed
NCT05903664 — Retinal Deep Phenotyping.TM · withdrawn
NCT06057493 — RDP Reliability Study · completed
NCT05903651 — Retinal Deep PhenotypingTM · completed
NCT06860555 — Hyperspectral Drusen Classification · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03420807 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Optina Diagnostics Inc.
Last refreshed: 28 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03420807.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing